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Description

The recent pandemic of SARS-CoV-2, which causes novel coronavirus disease 2019
(Covid-19), has had devastating impact on a global and national scale. In order to overcome
this outbreak it is imperative we find treatments that are safe and effective. To date, no
definitive treatment is available that can curtail the spread of this viral syndrome. Convalescent plasma (CP) is one such option that has repeatedly served as an important tool in
treatment of various bacterial and viral infections, especially in the setting of no specific
antimicrobial or vaccination against an infectious disease. Herein, we review the history of
CP, prior usage of CP in various infections and pandemics to date, mechanism of action of
the same and conclude with a brief overview of the experience gained so far with use of CP
in COVID-19.
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Introduction

Convalescent plasma (CP) as a means of
therapy against infectious diseases dates back
to the late 19th century. Over the course of
the past 150 years incremental developments
were made on how immunity and protection
can be conferred using this mode of therapy.
However, advances in antimicrobial and vaccine
technologies in the past 50 years that helped
eradicate or control several infectious diseases have pushed the CP methodology into the
background. The current pandemic of coronavirus disease 2019 (COVID-19), caused by a novel
severe acute respiratory syndrome coronavirus-2 (SARS CoV-2), has reignited interest in
passive immunity as a therapeutic option. It
has been driven largely due to the absence of
successful antimicrobials or effective vaccines
to counter the infection. As of this publication,
there are approximately 10 million cases detected worldwide with approximately 500,000
deaths attributed to the same.1
In this article, we review the history of usage of
CP in various infections and pandemics to date,
mechanism of action of CP and conclude with

a brief overview of the experience gained so far
with use of CP in COVID-19.

History of Convalescent Plasma

The concept of using serum therapy, as it was
originally known, dates back to as early as late
19th century. In the 1870s, Maurice Raynaud
(the same physiologist who first described Raynaud’s disease) described a concept akin to cell
mediated immunity while studying vaccinia virus when he concluded that the virus inside the
lymph nodes was able to elicit an “elaborated
lymph,” which conferred systemic immunity.2, 3
Concurrently in the 1880s, Auguste Chauveau, a
French veterinarian, proposed a concept of humoral immunity, wherein microorganisms produced some unknown substance within their
host’s blood that are harmful to themselves.2,
4
While his experiments with Bacillus anthracis
were deemed a failure, the concept nevertheless led to additional work by Charles Richet
and Jules Hericourt. Working with Staphylococcus pyosepticus, they noted dogs were naturally
resistant to this bacterium, whereas rabbits
were not. They hypothesized that immunity
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could be transmitted from dogs to rabbits by
transfer of blood. In their studies in 1888, they
were able to demonstrate protection in rabbits
that were transfused with immune blood from
healthy dogs. The two sentinel observations
in their study on rabbits challenged with S.
pyosepticus were: blood transfusion conferred
immunity against the bacterium in rabbits, and
immunity was stronger if donor blood came
from dogs that were accidentally inoculated by
the bacterium a few months prior.2, 5, 6 Herein,
Richet and Hericourt had discovered a new immunization method against infectious diseases
based on transfer of humoral immunity from
an immune animal to a nonimmune animal.
With the initial framework laid down by the
Frenchmen, in 1890, the German physiologist
Emil von Behring and his Japanese student

Shibasaburo Kitasato demonstrated that
transfer of blood from a rabbit immune to
tetanus toxin could confer immunity to the
disease in nonimmune rabbits.7, 8 Specifically,
they revolutionized the immunization concept
using toxins instead of whole/live microbes and
proved the clinical success of serotherapy.7 They
are credited with the discovery of the immunoglobulin purification technique and its application as a potential therapeutic option in human
disease. For this discovery, in 1901, Behring and
Kitasato were awarded the first Nobel Prize for
Medicine.
By the turn of the century, serum therapy was
available for various infectious diseases including diphtheria, tetanus, botulism and scarlet
fever (Table 1). Treatment with immune serum
was performed successfully and saved the lives

Table 1. Infectious diseases treated with convalescent human serum.
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Bacteria

Disease

Bacillus anthracis

Anthrax

Bordetella pertussis

Whooping cough

Clostridium botulinum

Botulism

Clostridium tetani

Tetanus

Corynebacterium diphtheria

Diphtheria

Group A streptococccus

Erysipelas, Scarlet fever

Neisseria meningitidis

Meningitis

Streptococcus pneumonia

Pneumonia

Viruses

Disease

Rubeola

Measles

Mumps virus

Mumps

Varicella-zoster virus

Chickenpox, Shingles

Hepatitis B virus

Hepatitis B

HIV-1

AIDS

Influenza A (H1N1)

1918 Pandemic Influenza

Influenza A (H5N1)

Influenza A

Respiratory syncytial virus

RSV infection

Ebola virus

Ebola

SARS-CoV

SARS

MERS-CoV

MERS

SARS-CoV-2

COVID-19
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of many individuals, specifically children with
diphtheria and soldiers with tetanus in World
War I.9 As early as 1907, serum from individuals
recovering from rubeola (measles) was used to
prevent infection in nonimmune individuals.9
Human serum was effective for prophylaxis in
measles, which at that time had a mortality
rate of 6–7% in some populations.10
On a relevant note, the Spanish influenza of
1918 was the first pandemic where the effectiveness of convalescent blood products was
clinically documented. A retrospective meta-analysis of eight studies from 1918–1925 involving 1703 patients was performed. An overall
case-fatality rate of 16% was found among patients treated with convalescent human blood
compared to 37% among those who did not.
Given these findings, the authors concluded
that patients with Spanish influenza pneumonia who received influenza-convalescent human
blood products may have experienced a clinically important reduction in the risk for death.11
Serum therapy was widely applied in pneumococcal disease and was found to be most
effective if it was initiated within three days of
onset of pneumococcal pneumonia.12, 13 Mortality of type 1 pneumonia could be reduced to
5% by administration of serum within the first
24 hours of onset of symptoms. By the early
1940s, serum therapy for pneumococcal pneumonia was standard practice and commercial,
type-specific sera were available for many of
the pneumococcal types.13
Serum therapy also had significant clinical and
mortality benefits in meningococcal meningitis. In 1905–1906, a major epidemic broke out in
New York City and along with a high mortality
rate of 70–80% provided a major impetus for
the development of serum therapy for Neisseria meningitis. Based on previous experimental
animal models, humans were treated with intrathecal and/or intravenous injection of horse
anti-meningococcal serum. Retrospective
analysis of data from several studies showed
statistically significant reduction in the rate
of mortality for serum-treated patient when
compared to untreated patients. Due to these
compelling results, anti-meningococcal serum
therapy became standard therapy and was recommended well into 1940s.13

It was not until the second half of the twentieth century when antibody-based therapies,
along with convalescent plasma preparations,
were developed for various viral syndromes,
including rabies, hepatitis A, hepatitis B, varicella-zoster virus and respiratory syncytial virus
(RSV).
Convalescent plasma therapy (CPT), as defined now, is collected via plasmapheresis from
patient survivors who have developed humoral immunity in the form of disease specific
antibodies, which can be transferred to other
patients to help them treat the same infection.
While antibiotics have largely replaced CPT in
bacterial infections, it is still a viable therapy
in viral infections in which no vaccine or other
treatment has been proven to be effective.
Serum therapy, while effective, was associated
in up to 10–50% patients with serum sickness,
secondary to antigen-antibody complex reaction, characterized by rash, arthralgia and
proteinuria. Improved antibody purification
methods did reduce toxicity, but the introduction of sulphonamides in the late 1930s led to
decreased use of serum therapy. Antimicrobial
therapy was less toxic, easier to administer,
showed consistent efficiency between lots, and
was overall more effective in eradicating bacterial infection.10 Serum therapy use, in contrast,
was more time consuming to prepare based
on bacterial strains, with significant lot-to-lot
and dosing variations, which led to decline and
eventual abandonment in serum therapy use by
the 1950s.
More recently, CPT has been successfully used
in the postexposure setting viral outbreaks
such as mumps, polio, measles, rabies, influenza, Middle East Respiratory Syndrome (MERS)
and Ebola, with positive changes in clinical
outcomes in some instances.14-17 Ebola virus
(EBOV) pandemic ravaged mainly Western
Africa from December 2013 to June 2016. In
the absence of a vaccine, initial management of
Ebola virus patients was essentially supportive
care, with fluid and electrolyte replacement,
and management of secondary complications.
In 2014, the World Health Organization proposed using convalescent blood products for
Ebola victims. Several patients recovering from
the Ebola virus received CPT, even as they were
intubated and receiving dialysis for multi-organ
failure.18 This recommendation was based on a
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study during an Ebola outbreak in Democratic
Republic of Congo in 1995. In this study, eight
patients were transfused with EBOV convalescent whole blood and seven recipients survived
accounting for a 12.5% case fatality rate compared with the overall case fatality rate of 80%
for the epidemic. However, it must be noted
that the authors could not conclude whether
CPT by itself or better supportive care primarily accounted for the survival benefit.19

How Does Convalescent Plasma
Work?

Convalescent blood products as a therapeutic
agent are believed to neutralize the pathogen,
while also activating a specific immune response leading to the eventual eradication of
the pathogen from the infected host. Several
forms of blood products have been used to
deliver this form of acquired passive immunity,
including convalescent whole blood, convalescent plasma or convalescent serum, pooled
immunoglobulins (Ig) for intravenous or intramuscular injections, high titer Ig fractions and
concentrated polyclonal or monoclonal antibodies.
The critical component in all convalescent
blood products is the antibody or Ig molecule,
especially those specific to the pathogen of interest. These mediators of humoral immunity
effect their actions through a variety of mechanisms that involve both the innate and adaptive
immune systems in the host they are delivered
into. While the degree of an individual mechanism in effecting pathogen clearance might be
difficult to assess, the cumulative action is believed to contribute to the eventual protective
response.20 (Figure 1) The mechanisms include
the following:
1. Neutralization of pathogen entry and replication,
2. Neutralization of toxins,
3. Neutralization of virulence factors,
4. Complement activation and evolution of
adaptive immune response,
5. Antibody-dependent cellular cytotoxicity
and
6. Antibody-dependent cellular phagocytosis.
To be clear, there is also the possibility of
worsening of disease to be considered when
exploiting CP as a therapeutic mode. This phe-
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nomenon is seen particularly in viral infections
like Dengue and Zika, where multiple serotypes
of the pathogen exists. Specifically, protective
antibodies against one serotype of Dengue,
but cross reactive with other serotypes are
known to stabilize the second serotype and
thereby facilitate entry within permissive cells,
which result in disease.21-23 In the instance of
Zika, both plasma from recovering patients and
virus specific monoclonal antibodies have been
shown to enhance infectivity in cell culture
models.24 For this reason, and the general risk
of other de novo viral transmission from plasma, the use of CP does need rigorous vetting
before implementation as a safe therapy in the
general population.

What Is the Role of Convalescent
Plasma in COVID-19?

In the case of COVID-19, history suggests as
the pool of COVID-19 survivors increase, CPT
has the potential to become a viable treatment
option.
A small study of 5 critically ill patients with confirmed COVID-19 and acute respiratory distress
syndrome (ARDS) was conducted at the Shenzhen Third People’s Hospital in Shenzhen, China, from January 20, 2020 to March 25, 2020,
and has served as a proof-of-concept of the
benefit of convalescent plasma infusion in this
population. Shen et al., found that the administration of CP-containing neutralizing antibodies (SARS-CoV-2-specific anti-IgG binding titer
> 1:1000) led to improvements in clinical status,
defined as decreased viral load, recovery from
COVID-19 and discharge from hospital.25
Similarly, a prospective study of convalescent
plasma in 10 patients with severe COVID-19 infection in three participating Chinese hospitals
in Wuhan, also showed improved clinical symptoms along with increased oxygen saturations
within just 3 days of CPT.26, 27 In addition to the
primary treatment endpoint of safety, this
study also showed improvement of additional
parameters, including improvements in lymphocyte counts, C-reactive protein and radiographic images when compared with pre-transfusion values or images. Of the 10 patients, viral
load was undetectable in seven patients after
CPT.
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Figure 1. Antibody mechanisms of action in eliminating a pathogen. Reprinted by permission from
Springer Nature: Springer Nature, Nature Reviews Immunology (Beyond binding: antibody effector functions in infectious diseases. Lenette L. Lu, Suscovich TJ, Fortune SM, Alter G.), Copyright
(2018).
Rajendran et al.28 recently published a comprehensive review on the efficacy and safety
of CPT in patients with COVID-19. Their review included five independent studies, one
conducted in South Korea and four in China,
comprising a total of 27 patients. They concluded that, in addition to treatment with other
antiviral and antimicrobial drugs, CPT proved to
be an effective therapeutic option with promising evidence on safety, improvement of clinical
symptoms and reduction in mortality.

As exciting and encouraging as these results
are, attention must be drawn to the complexities of using antibodies as a treatment for
highly-pathogenic viruses such as the SARSCoV-2 virus. For example, a 2019 study in Rhesus monkeys showed that monkeys immunized
with vaccines (containing SARS-CoV spike
proteins) and confirmed to have developed
high titers of neutralizing anti-spike antibodies
before inoculation with SARS-CoV, experienced
a more severe lung injury when compared with
143
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their non-immunized controls, despite having
lower viral loads.29 A recent retrospective study
in China found that when CP was infused immediately after the first detection of viral shedding, all six patients tested negative for SARSCoV-2 RNA just 3 days after infusion; however,
five patients eventually died, suggesting that
CPT can halt SARS-CoV-2 shedding but does
not improve mortality in critically-ill, end-stage
COVID-19 patients.30 A possible explanation for
these findings is that in the presence of antibodies, the disease burden is shifted to other
immune cells such as macrophages, as has
been demonstrated in vitro.31 Dysregulated innate immune responses, typical of severe acute
lung injuries, may ensue with the involvement
of macrophages.
Based on these small pilot studies, CPT for
COVID-19 treatment has gained much attention, especially with no known effective treatment to date. It is important to understand
how to best utilize convalescent plasma and
in what setting. So far, the emphasis has been
on patients with severe disease who have run
out of treatment options. However, previous
experiences in disease outbreaks mentioned
earlier, show that CPT works best when used
as prophylaxis or earlier in the disease process, as treatment. This important point was
demonstrated in 2002–2004 SARS outbreak,
where patients who received CPT within two
weeks experience significantly better clinical outcomes when compared to those who
received it after two weeks.32 The optimal dose
and time of administration, as well as the
clinical benefits of CPT in COVID-19, need to be
better characterized and further investigated
in the context of the above variables in better
controlled studies.
As of June 2020, the United States Food and
Drug Administration (FDA) has published on
its website guidelines on three separate pathways for the use of CPT. Briefly, the following
pathways are currently available for administering CPT or studying its utility: (1) Clinical
Trials—investigators can submit requests, via
email, to the FDA under the traditional investigational new drug (IND) regulatory pathway;
(2) Expanded Access—this pathway includes
an IND application to include the use of CPT
in COVID-19 patients, not eligible or unable to
participate in RCTs, and who have immediately
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life-threatening COVID-19; (3) Single Patient
Emergency IND—allows the licensed physician
to request a single patient emergency IND
for their patients deem to have immediately life-threatening COVID-19, and are unable,
for various reasons, to participate in RCTs.
Full details about these pathways and how to
apply for participation are found on the FDA
website.33 Following these provisions, CPT is
underway; mass calls for recovered COVID-19
patients to donate plasma is ongoing. For example, the COVID-19 expanded access program
already has more than 2000 plasma collection
sites, more than 5000 participating licensed
physicians and more than 7000 infusions done
already.34
According to FDA’s latest guidelines, potential
donors must have had a documented SARSCoV-2 infection, be symptom-free for at least
14 days and meet standard blood donor eligibility requirements. However, a negative result
for COVID-19 by a diagnostic test is no longer
necessary to qualify as a donor. While testing
donor plasma for minimum neutralizing antibody titer (1:160, meaning 1-in-160 dilution of
a given unit of plasma has activity against the
virus) is recommended, this is not being done
at testing facilities due to the lack of widely available, high-throughput, enzyme-linked
immunosorbent assay (ELISA) based SARSCoV-2 tests.33 Typically, plasma donations are
only permitted every 28 days; however, due to
high demand some collection sites are permitting eligible donors to donate every 7 days for a
period of 28 days.

Conclusion

Although supported by a few small studies,
and limited numbers of patients, CPT is appearing as a promising therapeutic modality to
counter COVID-19. Questions remain on how
or whether CPT influences the spectrum of the
COVID-19 disease severity. Answers on a number of relevant variables, such as ideal timing of
use (prophylactic versus early pre-symptomatic
phase versus mildly symptomatic phase versus severe terminal phase), appropriate dose/
number of infusions, standardization of donor
antibody titers, will help address these questions. In addition, data about induced innate
immune response by dysregulation of the
immune system by CPT, which could potentially
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lead to increased toxicity and mortality need to
be addressed to ensure safety of this methodology.
Nevertheless, in light of its long history, combined with absence of an effective vaccine or
antiviral, CPT remains a worthy candidate as a
therapeutic option to address COVID-19.
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